379 related articles for article (PubMed ID: 10925331)
21. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
22. An audit of the use and complications of glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention against national UK standards.
Sheikh A; Baig K
Cardiovasc Revasc Med; 2006; 7(4):237-9. PubMed ID: 17174871
[TBL] [Abstract][Full Text] [Related]
23. The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes.
Koller CF
Heart Lung; 2001; 30(5):321-9; quiz 330-1. PubMed ID: 11604974
[TBL] [Abstract][Full Text] [Related]
24. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Juran NB
Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
[TBL] [Abstract][Full Text] [Related]
25. Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
Anderson JR; Riding D
Cardiol Rev; 2008; 16(4):213-8. PubMed ID: 18562812
[TBL] [Abstract][Full Text] [Related]
26. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
Gowda RM; Khan IA; Vasavada BC; Sacchi TJ
Am J Ther; 2004; 11(4):302-7. PubMed ID: 15266223
[TBL] [Abstract][Full Text] [Related]
27. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Tcheng JE
Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
[TBL] [Abstract][Full Text] [Related]
28. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM
J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346
[TBL] [Abstract][Full Text] [Related]
29. Acute profound thrombocytopenia following abciximab therapy.
Bishara AI; Hagmeyer KO
Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
[TBL] [Abstract][Full Text] [Related]
30. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
Wu KK; Willerson JT
Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
[No Abstract] [Full Text] [Related]
31. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
Fahdi IE; Saucedo JF; Hennebry T; Ghani M; Sadanandan S; Garza-Arreola L
Am J Cardiol; 2004 Feb; 93(4):453-5. PubMed ID: 14969621
[TBL] [Abstract][Full Text] [Related]
32. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
Dorsch MP; Montague D; Rodgers JE; Patterson C
Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
[TBL] [Abstract][Full Text] [Related]
33. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
[TBL] [Abstract][Full Text] [Related]
34. [Clinical use of glycoprotein IIb/IIIa inhibitors].
Simonetti I; Gallopin M; Gensini GF
Ann Ital Med Int; 1998; 13(3):163-8. PubMed ID: 9859573
[TBL] [Abstract][Full Text] [Related]
35. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.
Aster RH
Chest; 2005 Feb; 127(2 Suppl):53S-59S. PubMed ID: 15706031
[TBL] [Abstract][Full Text] [Related]
36. Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes.
Marsh JD
Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S15-26. PubMed ID: 12434711
[TBL] [Abstract][Full Text] [Related]
37. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.
Abrams CS; Cines DB
Curr Hematol Rep; 2004 Mar; 3(2):143-7. PubMed ID: 14965491
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
Brouse SD; Wiesehan VG
Ann Pharmacother; 2004 Nov; 38(11):1783-8. PubMed ID: 15383640
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
Cheng JW
Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
Brown DL; Fann CS; Chang CJ
Am J Cardiol; 2001 Mar; 87(5):537-41. PubMed ID: 11230835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
